



29 July 2009

Companies Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

ASX ANNOUNCEMENT / MEDIA RELEASE

ANTEO DIAGNOSTICS ENTERS COMMERCIAL DISCUSSIONS

Key Points:

- **Anteo's Mix&Go technology has received positive reviews by a number of potential international clients who are international bead manufacturers and in vitro diagnostic suppliers.**
- **Anteo has successfully demonstrated its Mix&Go technology to these clients who have been able to replicate data generated by Anteo.**
- **As a result Anteo has entered into commercial discussions with them.**

Background:

Mix&Go is Anteo's most progressed product offering. It is a coating that improves the performance of the magnetic beads that form the basis of many pathology tests. In addition, use of the process leads to significant cost reductions for the manufacturers of these pathology tests.

In the past customers have not been able to routinely replicate the high quality results that Anteo has been able to generate internally. Rigorous processes have now been established that have allowed effective transfer of the technology to third parties such as international bead manufacturers and in vitro diagnostic suppliers who make the test kits that are used by pathology laboratories.

***Anteo Diagnostics Limited* ABN 78 090 487 273**

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com



Commercial Progress:

- **Mix&Go treated beads have been shown, in the hands of large international organisations, to have increased stability, improved sensitivity and a broader dynamic range than untreated beads.**
- **Independent third parties have reported that Mix&Go treated beads are easier to handle and and that the tests are faster to produce.**
- **Anteo has signed six Confidentiality Agreements and/or Material Transfer Agreements with various parties, including global bead manufacturers and in vitro diagnostics (IVD) suppliers.**
- **A number of face to face discussions have been held with potential partners in the US and Europe that are expected to the execution of licensing or revenue generating agreements.**

Interest in the Mix&Go product has been expressed by market participants in all major geographies and across the market spectrum from global bead manufacturers to major IVD suppliers and the research market. These market participants include some of the leading global healthcare companies.

Dr Geoff Cumming, Anteo Managing Director, said “I am pleased with the significant progress made in the promotion and validation of the core Mix&Go product. This has been achieved through the rigour injected into the scientific endeavours by the Anteo team over the last 12 to 18 months. I am looking forward to progressing discussions with a view to securing meaningful maintainable revenue streams as quickly as possible.

Anteo Chairman, Mr James Henderson also noted that “the keen interest from several of the world’s largest healthcare companies highlighted the potential value of the Mix&Go technology and provides strong endorsement of the cost efficiencies and competitive advantages to be achieved by these companies from its use.” Mr Henderson noted that “with these developments he hoped the market would realise the value of the Company’s IP and assets, ultimately leading to a re-rating of Anteo’s prospects”.

For further information please contact:

Dr Geoff Cumming, CEO, Anteo Diagnostics Limited
Tel: +612 8823 3110

Mr James Henderson, Non Executive Chairman, Anteo Diagnostics Limited
Tel: +612 8823 3100

Anteo Diagnostics Limited ABN 78 090 487 273
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com



About Anteo

Anteo Diagnostics is an Australian company specializing in the design and assembly of multi-component coatings for the solid phase of immunoassay and the use of those coatings in biomarker development. Anteo's proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. This results in dramatically improved immunoassay performance such as better sensitivity, and cost savings such as batch-to-batch reproducibility. Anteo applies its coatings to develop novel biomarkers for a range of diseases. Anteo works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.biolbio-layer.com

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com